López-Altamirano KF, Rascón-Martínez DM, Guevara-López U, Terrazas-Luna VM, Aguilar-Cózatl I, Zamudio-Jaramillo RE, Cruz-Martínez J, Daniel-Zacarías G, Tomax-Deolarte D, Villalobos-Villegas L

Language: Spanish
References: 20
Page: 28-32
PDF size: 406.46 Kb.

ABSTRACT

Introduction: in Intensive Care (IT), sedoanalgesia is applied, but it is not directed to a final clinical outcome that is dignified and without suffering, considered a fundamental basic human right. Objective: to evaluate the degree of palliative sedoanalgesia applied to patients in Intensive Care at the Hospital General de Zona (HGZ) 20 IMSS Puebla. Material and methods: longitudinal, quasi-experimental, prospective, analytical study. Patients requiring palliative care in intensive care were analyzed. A total of 14 patients with ventilatory support who were not recovering according to the SOFA scale were included. Palliative sedation: midazolam and/or propofol according to the degree of sedation assessed by the Richmond Agitation Sedation Scale (RASS) and the Analgesia, Behavioral Pain Scale (BPS); we administered fentanyl. Standardized rescue sedation and analgesia. SPIKES protocol for the psychological and/or religious support network for family members. Results: two patients (14.2%) were outside the goal ranges before the start of palliative sedation, they later reached goals. All patients with Fentanyl did not require rescue analgesia compared to buprenorphine, statistically significant p = 0.047. Conclusion: sedative and palliative analgesic effects of the drugs used, palliative sedoanalgesia, in patients in the agonic phase, provides hemodynamic control, analgesic and adequate sedation.

REFERENCES

1. De Lima L, Bruera E. The Pan American Health Organizations: Its structure and role in the development of a palliative care program for Latin America and the Caribbean. J Pain Symptom Manage. 2000: 20: 440-448.

2. Guevara U. Lineamiento general para la atención paliativa de pacientes COVID-19 y no COVID durante la pandemia 2020. México: Instituto Medicina del Dolor y Cuidados Paliativos A.C. (IMEDOCP); 2020. p. 4-32.

3. Secretaría de Salud. Programa Nacional de Capacitación en Cuidados Paliativos para equipos de primer contacto en atención primaria. México: Secretaría de Salud; 2016.

4. Angus DC, Barnato AE, Linde-Zwirble WT. Use of intensive care at the end of life in the United States: An epidemiologic study. Crit Care Med. 2004; 32: 638-643.

5. Wennenberg JE, Cooper MM. The Darthmouth Atlas of Health Care in the United States: A report on the Medicare Program. Chicago: American Hospital Publishing; 1990.

6. Breen CM, Abernethy AP, et al. Conflict associated with decisions to limit life-sustaining treatment in intensive care units. J Gen Intern Med. 2001; 16: 283-289.

7. Herrera A, Ríos M, Manriquez JM, Entrega de malas noticias en la práctica clínica. Rev Médica Chile. 2014; 142: 1306-1315.

8. Puntillo KA, Morris AB, et al. Pain behaviors observed during six common procedures: results from Thunder Project II. Crit Care Med. 2004; 32: 421-426.

9. Sprung CL, Cohen LS, Baras M, Bulow HH, Hovilehto S, et al. End-of-life Practices in European Intensive Care Units. The Ethicus Study. JAMA. 2003; 290: 790-797.

10. Sessler CN, Gosnell MS, Brophy GM, O'Neal PV, Keane KA, et al. The Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patients. Am J Respir Crit Care Med. 2002; 166: 1338-1344.

11. Payen J, Bru O, Lagrasta A, Novel E, Deschaux I, et al. Assessing pain in critically ill sedated patients by using a behavioral pain scale. Crit Care Med. 2001; 29: 2258-2263.

12. Hudson P, Remedios C, Zordan R, Thomas K, Clifton D, Crewdson M, et al. Guidelines for the psychosocial and bereavement support of family caregivers of palliative care patients. J Palliat Med. 2012; 15: 696-702.

13. WHO Model List of Essential Medicines (19th list). Geneva: World Health Organization; 2015 Disponible en: http://www.who.int/medicines/publications/essentialmedicines/EML2015_8-May-15.pdf

14. Yokomichi N, Yamaguchi T, Maeda I, Mori M, Imai K, Shirado-Naito A, et al. Effect of continuous deep sedation on survival in the last days of life of cancer patients: a multicenter prospective cohort study. Palliat Med. 2022; 36: 189-199.

15. Maeda I, Morita T, Yamaguchi T, Inoue S, Ikenaga M, Matsumoto Y, et al. Effect of continuous deep sedation on survival in patients with advanced cancer (J-Proval): a propensity score-weighted analysis of a prospective cohort study. Lancet Oncol. 2016; 17: 115-122.

16. Belar A, Arantzamendi M, Payne S, Preston N, Rijpstra M, Hasselaar J, et al. How to measure the effects and potential adverse events of palliative sedation? An integrative review. Palliat Med. 2021; 35: 295-314.

17. Fredheim OM, Skulberg IM, Magelssen M, Steine S. Clinical and ethical aspects of palliative sedation witpropofol: a retrospective quantitative and qualitative study. Acta Anaesthesiol Scand. 2020; 64: 1319-1326.

18. Setla J, Pasniciuc SV. Home palliative sedation using phenobarbital suppositories: time to death, patient characteristics,and administration protocol. Am J Hosp Palliat Care. 2019; 36: 871-876.

19. Bodnar J. A review of agents for palliative sedation/continu- ous deep sedation: pharmacology and practical applications. J Pain Palliat Care Pharmacother. 2017; 31: 16-37.

20. Swart SJ, Brinkkemper T, Rietjens JA, Blanker MH, van Zuylen L, Ribbe M, et al. Physicians' and nurses' experiences with continuous palliative sedation in the Netherlands. Arch Intern Med. 2010; 170: 1271-1274.